Left atrial appendage (LAA) closure with the new-generation Watchman FLX device (Boston Scientific) provides a high rate of effective closure with few early adverse events, according to results of ...

The newer-generation Watchman device was associated with sustained safety and efficacy out to 2 years when implanted in people at high thromboembolic risk, the PINNACLE FLX IDE study group reported.

SAN FRANCISCO, CA—The redesigned Watchman FLX device (Boston Scientific) provides safer left atrial appendage occlusion (LAAO) in patients with atrial fibrillation compared with the first-generation ...

(RTTNews) - Boston Scientific (BSX) said that 24-month results from the PINNACLE FLX clinical trial demonstrated the safety and performance of WATCHMAN FLX left atrial appendage closure device for ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows.

MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

Quite a few people with atrial fibrillation have gotten off blood thinners through the Watchman, a device installed within the body to prevent blood clots from leaving the left atrial appendage. That ...